Previous 10 | Next 10 |
Company to host webinar event on May 16 th presenting new clinical data from the 4WHIM Phase 3 trial; oral presentation to follow on May 21 st at the 2023 Clinical Immunology Society (CIS) Annual Meeting U.S. NDA submission of mavorixafor for WHIM s...
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the fi...
2023-04-12 14:50:38 ET X4 Pharmaceuticals ( NASDAQ: XFOR ) added ~22% on Wednesday, marking the biggest intraday gain in over six months after announcing upcoming data readouts for its lead candidate mavorixafor in rare immune disease WHIM syndrome. The company said that n...
X4 to host virtual investor event on Tuesday, May 16 CIS oral presentation to take place on Sunday, May 21 BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeuti...
2023-04-12 04:29:29 ET Summary Positive P3 results of mavorixafor for first-ever treatment of WHIM syndrome with possible BLA approval in 1H 2024. A large chronic neutropenia market could see their first approved drug in over 30 years. The current market cap is $100M and cash ...
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced that, effective on March 31, 2023, the company issued induceme...
2023-03-28 07:33:10 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! Moving stocks this morning are clinical trials, earnings rep...
2023-03-21 12:08:09 ET X4 Pharmaceuticals, Inc. (XFOR) Q4 2022 Earnings Conference Call March 21, 2023, 09:00 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Paula Ragan - CEO Adam Mostafa - CFO Murray Stewart - Interim Chief Medical Officer M...
2023-03-21 06:07:01 ET X4 Pharmaceuticals press release ( NASDAQ: XFOR ): Q4 GAAP EPS of -$0.29 misses by $0.05 . X4 had $123.0 million in cash, cash equivalents, and restricted cash as of December 31, 2022. X4 believes that it has sufficient funds to support compa...
Upcoming expected milestones for investigational therapy mavorixafor in WHIM syndrome include: presentation of additional Phase 3 clinical data in 2Q 2023, NDA submission in early 2H 2023, and potential U.S. launch in 1H 2024 Announcement of data from ongoing chronic neutropenia...
News, Short Squeeze, Breakout and More Instantly...
X4 Pharmaceuticals Inc. Company Name:
XFOR Stock Symbol:
NYSE Market:
X4 Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date Durable mean ANC levels above the lower limit of normal for CN were achieved for partic...
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will host a virtual investor event on Thursday, June 27, 2024 at 8:00 am ET. To register for the eve...